Literature DB >> 33911569

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma.

Jiyoung Rhee1, Jaemin Jo1, Sang-Hoon Han1, Jung-Mi Kwon1.   

Abstract

No effective systemic chemotherapy is well-established in basal cell carcinoma. We report a case with three simultaneous malignancies: colon cancer, basal cell carcinoma, and smoldering multiple myeloma. The patient was treated with capecitabine and oxaliplatin after surgery for colon cancer. Surprisingly, he achieved a complete response for basal cell carcinoma. This is the first report of this chemotherapy regimen in basal cell carcinoma. This finding suggests that combination capecitabine and oxaliplatin can be a treatment option for patients unable to receive local therapy.
Copyright © 2019 The Korean Dermatological Association and The Korean Society for Investigative Dermatology.

Entities:  

Keywords:  Basal cell carcinoma; Capecitabine; Chemotherapy; Oxaliplatin

Year:  2019        PMID： 33911569      PMCID： PMC7992662          DOI： 10.5021/ad.2019.31.2.201

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


  17 in total

Review 1.  Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature.

Authors:  K Moeholt; H Aagaard; P Pfeiffer; O Hansen
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

Review 2.  Basal-cell carcinoma.

Authors:  Adam I Rubin; Elbert H Chen; Désirée Ratner
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

3.  Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine.

Authors:  Bart T Endrizzi; Peter K Lee
Journal:  Dermatol Surg       Date:  2009-07-28       Impact factor: 3.398

4.  Capecitabine for skin cancer prevention in solid organ transplant recipients.

Authors:  Tanawat Jirakulaporn; Bart Endrizzi; Bruce Lindgren; Josy Mathew; Peter K Lee; Arkadiusz Z Dudek
Journal:  Clin Transplant       Date:  2010-11-02       Impact factor: 2.863

Review 5.  Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer.

Authors:  Apar Kishor Ganti; Anne Kessinger
Journal:  Cancer Treat Rev       Date:  2011-01-07       Impact factor: 12.111

6.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

7.  Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea.

Authors:  Chang-Mo Oh; Hyunsoon Cho; Young-Joo Won; Hyun-Joo Kong; Yun Ho Roh; Ki-Heon Jeong; Kyu-Won Jung
Journal:  Cancer Res Treat       Date:  2017-07-14       Impact factor: 4.679

Review 8.  Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Authors:  Frank Cirrone; Christy S Harris
Journal:  Clin Ther       Date:  2012-10-01       Impact factor: 3.393

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

Review 10.  Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.

Authors:  A Aggarwal; T Fojo; C Chamberlain; C Davis; R Sullivan
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.